Physician profile
Michael A Cassetta
NPI 1811916505
$17,717.01
in general payments reported to CMS, 2019-2025
54 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,454 · 2020: $1,397 · 2021: $1,549 · 2022: $4,062 · 2023: $3,828 · 2024: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,121 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,121.48 |
| Education | $133.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $3,485.57 | 2019-2023 | Krystexxa |
| Amgen INC. | $2,324.06 | 2019-2024 | Otezla, Enbrel, Tavneos |
| Abbvie INC. | $2,188.24 | 2019-2024 | Skyrizi, Rinvoq, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,188.69 | 2019-2024 | Saphnelo, Farxiga |
| Pfizer INC. | $1,053.24 | 2019-2023 | |
| Janssen Biotech, INC. | $1,040.33 | 2019-2024 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $764.82 | 2019-2024 | Jardiance, Taltz, Mounjaro |
| Mallinckrodt Hospital Products INC. | $578.88 | 2020-2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $543.24 | 2019-2024 | Jardiance, Cyltezo |
| Ucb, INC. | $489.97 | 2021-2024 | Cimzia |
| Merck Sharp & Dohme LLC | $408.37 | 2019-2024 | Verquvo, Gardasil 9, Belsomra |
| Corcept Therapeutics | $407.35 | 2019-2024 | Korlym |
| Novo Nordisk INC | $403.70 | 2019-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $327.99 | 2019-2023 | Benlysta, Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $274.04 | 2019-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cassetta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.